CCR1


Also found in: Acronyms.

CCR1

A gene on chromosome 3p21 that encodes a member of the beta chemokine receptor family, whose ligands include macrophage inflammatory protein 1 (MIP-1) alpha, regulated on activation normal T expressed and secreted protein (RANTES), monocyte chemoattractant protein 3 (MCP-3) and myeloid progenitor
inhibitory factor-1 (MPIF-1). The protein product transduces a signal by increasing intracellular calcium, and drives stem cell proliferation.
References in periodicals archive ?
In the above example, the CPA translation of the Greek verb has an independent pronoun in one manuscript (CCR1), but an enclitic in another ([CSRPd]).
The report provides comprehensive information on the C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
reported that soluble UL128 protein (1000 ng/mL) in vitro could block migration of monocytes by down-regulation of CCR1, CCR2 and CCR5 comparing with monocytes infected with wild type of HCMV.
It is upregulated by inflammatory stimuli and induces leukocyte recruitment to inflamed tissues via interacting with two chemokine receptors CCR1 and CCR5 on inflammatory cell surface.
The f valuestartedtodropand reached0at nd = 0.45 when the first complete loss event for "CCR1 chemokine receptor binding" was recorded.
Meddahi-Pelle et al., "RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans," Angiogenesis, vol.
Yeaman, Mice lacking the chemokine receptor CCR1 show increased susceptibility to toxoplasma gondii infection, The Journal of Immunology, 166, 1930-1937 (2001).
Furthermore, targeting antigens to chemokine receptors [1] on DCs (CCR1, CCR2, CXCR4, CCR5, CCR6, and CXCR1) generates enhanced immune responses in vitro and in vivo.
(Nasdaq:CCXI) has announced publication of positive data from the company's Phase 2 CARAT-2 study for CCX354, a potent and selective, orally-administered inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).
6 January 2012 - US ChemoCentryx Inc said on Thursday that UK GlaxoSmithKline (LON:GSK) has exercised its option to gain an exclusive licence for further development and worldwide commercialisation of CCX354, a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).
The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling.